Friday, 19 Oct 2018

You are here

FDA's Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Finalized

In response to the growing opioid crisis, the US Food and Drug Administration has approved the final Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), designed to reduce the risk of abuse, misuse, addiction, overdose, and deaths due to prescription opioid analgesics. This expanded REMS applies to immediate-release (IR) and to the extended-release and long-acting (ER/LA) opioid analgesics.  (Citation Source: http://bit.ly/2DaIllV)

The Goal of the Opioid Analgesic REMS is to ensure that the benefits of these drugs continue to outweigh the risks. 

The REMS program requires that training be made available (but not mandated) to all health care providers (HCPs) who are involved in the management of patients with pain, including nurses and pharmacists. Opioid manufacturers with approved opioid analgesics will provide unrestricted grants to accredited continuing education providers for the development of education courses for HCPs based on the FDA Education Blueprint.

The FDA believes that all HCPs involved in the management of patients with pain should be educated about the fundamentals of acute and chronic pain management and the risks and safe use of opioids so that when they write or dispense a prescription for an opioid analgesic and monitor patients receiving these medications. 

There is no mandatory federal requirement that prescribers or other HCPs take the training and no precondition to prescribing or dispensing opioid analgesics to patients. However, the FDA’s Opioid Policy Steering Committee continues to consider whether there are circumstances when the FDA should require some form of mandatory education for HCPs.

The new REMS also requires that the education cover broader information about appropriate pain management, including alternatives to opioids for the treatment of pain. 

Originally introduced in 2012, the new modified Opioid Analgesic REMS now requires that 347 opioid analgesics intended for outpatient use be subject to these REMS requirements. The REMS program continues to include Medication Guides for patients and caregivers to read, new Patient Counseling Guides to assist health care providers with important discussions with patients, and plans for assessing the program’s effectiveness.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Complex Pain Syndromes in the Emergency Room

Emergency physician Chris Hahn, MD, doesn't have any trouble conjuring a simple definition of fibromyalgia. "Just think about the most annoying chief complaints you can imagine. That's the diagnostic criteria."

Carpal Tunnel Syndrome - a Leading Cause of Work Related Disability

MMWR reports that workers’ compensation claims for carpal tunnel syndrome (CTS) in California during 2007–2014 were 6.3 per 10,000 full-time equivalent workers, with female workers and workers in industries that manufacture apparel, process food, and perform administrative work being at highest risk for CTS.

Anxiety and Depression are Common in Arthritis Patients

The high prevalence of symptoms of anxiety and depression among adults with arthritis warrants awareness, screening, and subsequent treatment of these conditions. Health care providers can refer patients to mental health professionals and self-management education programs, and encourage physical activity to reduce anxiety and depression symptoms and improve quality of life.

Lower Income Elderly are More Likely to Use Opioids

The Journal of Gerontology reports that the poorest of the elderly are the most likely to receive prescription opioids.

Unsafe Practices with Ambien Use

Ambien (zolpidem) is the most widely used prescription hypnotic sedative since its introduction in 1992 and is currently the fourth most frequently prescribed psychiatric drug (2013). Recent US Food and Drug Administration Drug Safety Communications suggest limitations on use to reduce adverse effects. A study of the Medical Expenditures Survey in 2015 revealed that over 3.8 million adults reported using one or more prescriptions for zolpidem.